Tyra Biosciences Inc. Common Stock TYRA · Stock Open Tyra Biosciences Inc. Common Stock in new tab
Tyra Biosciences Inc. Common Stock Analysis (TYRA)
Is Tyra Biosciences Inc. Common Stock a good investment? Tyra Biosciences Inc. Common Stock (TYRA) is currently trading at 27.99 USD. Market analysts have a consensus price target of 45.85 USD. This suggests a potential upside from current levels.
Earnings Schedule: Tyra Biosciences Inc. Common Stock is expected to release its next earnings report on Nov. 4, 2026. The market consensus estimate for Forward EPS is -2.27.
Investor FAQ
Does Tyra Biosciences Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Tyra Biosciences Inc. Common Stock?
Tyra Biosciences Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 4, 2026. The company currently has a trailing EPS of -1.88.
Company Profile
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Community Discussion